Ledipasvir-sofosbuvir in patients with hepatitis C virus genotype 5 infection: an open-label, multicentre, single-arm, phase 2 study.

@article{Abergel2016LedipasvirsofosbuvirIP,
  title={Ledipasvir-sofosbuvir in patients with hepatitis C virus genotype 5 infection: an open-label, multicentre, single-arm, phase 2 study.},
  author={Armand Abergel and Tarik Asselah and Sophie M{\'e}tivier and Kathryn Kersey and Deyuan Jiang and Hongmei Mo and Phillip S. Pang and Didier Samuel and Veronique Loustaud-Ratti},
  journal={The Lancet. Infectious diseases},
  year={2016},
  volume={16 4},
  pages={459-64}
}
BACKGROUND Data about the response of hepatitis C virus (HCV) genotype 5 to approved and experimental treatment regimens are scarce. We assessed the efficacy and safety of combination therapy with the NS5A inhibitor ledipasvir and the NS5B polymerase inhibitor sofosbuvir in patients with HCV genotype 5. METHODS We did this open-label, multicentre, single-arm, phase 2 trial at five hospitals in France. Eligible patients were at least 18 years old and had chronic infection with HCV genotype 5… CONTINUE READING
Related Discussions
This paper has been referenced on Twitter 58 times. VIEW TWEETS

Citations

Publications citing this paper.

References

Publications referenced by this paper.
Showing 1-10 of 20 references

C-salvage: grazoprevir (GZR; MK-5172), elbasvir (EBR; MK-8742) and ribavirin (RBV) for chronic hcv-genotype 1 (GT1) infection after failure of direct-acting antiviral (DAA) therapy

X Forns, S Gordon, Zuckerman
J Hepatol 2015; • 2015

Optimal IFN-free therapy in treatment-naïve patients with HCV genotype 1 infection.

Liver international : official journal of the International Association for the Study of the Liver • 2015

All oral treatment for genotype 4 chronic hepatitis C infection with sofosbuvir and ledipasvir: interim results from the NIAID SYNERGY Trial

R Kapoor, A Kohli, S Sidharthan
Hepatology • 2014

Similar Papers

Loading similar papers…